Herceptin: What it took to make it happen

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

One day in 1996, in my role as chief science correspondent for NBC News, I was rummaging through the usual huge (pre-internet) pile of press releases on my desk and zeroed in on one: a phase III trial of a treatment for an aggressive type of breast cancer that was desperate to accrue volunteers.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Robert Bazell
Adjunct professor of molecular, cellular and developmental biology, Yale University
Table of Contents

YOU MAY BE INTERESTED IN

For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.
Robert Bazell
Adjunct professor of molecular, cellular and developmental biology, Yale University

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login